REGULATORY

• Japan Begins FY2026 CEA Reform Talks, Re-Designation after Market Expansion Up for Debate
  July 17, 2025

• Astellas Employee Sentenced to 3.5 Years in China for Spying
  July 17, 2025

• Verdict Due July 16 for Astellas Employee Detained in China
  July 14, 2025

• Japan’s Major Parties Outline Various Drug Policy Visions Ahead of Upper House Poll
  July 14, 2025

• Japan to Survey Drug Waste at Pharmacies amid Rising Concerns Over Disposal Costs
  July 11, 2025

• Generic and Wholesaler Groups Call for Pricing Reforms to Reflect Inflationary Pressures
  July 11, 2025

• 16 Drugs Enter Japan Trials after Pro-Innovation Reform: Industry Poll
  July 10, 2025

• Leqembi Likely to Face 15% Price Cut Under Special CEA Rule
  July 10, 2025

• Janssen’s Balversa Gets Green Light for NHI Listing
  July 10, 2025

• Pharma Groups Renew Push for Price Stability During Patent Term as FY2026 Reform Talks Begin
  July 10, 2025

• Trade Groups Urge Pricing Overhaul for Regenerative Medicines, Biotech Drugs
  July 10, 2025

• PMDA to Clarify Position on Japanese PI Trials at August Symposium amid Industry Confusion
  July 10, 2025

• J-ENTRY Consortium Steps Up to Develop Two “Drug Loss” Products
  July 9, 2025

• Vyjuvek Gel, 1st Topical Gene Therapy, Poised for Approval in Japan
  July 8, 2025

• Japan Panel Backs Shift to PCV20 for Pneumococcal Vaccination in Elderly
  July 8, 2025

• AMED to Promote Earlier Out-Licensing to Industry to Bridge the “Devil’s River”: New Chief
  July 8, 2025

• Semaglutide, Tirzepatide, and More Drugs under PMDA Safety Review
  July 7, 2025

• Japan to Overhaul Diabetes Trial Guidelines to Align with Global Standards and Prevent Drug Lag/Loss
  July 7, 2025

• Healthcare-Linked Candidates Launch Campaigns as Upper House Election Gets Underway
  July 4, 2025

• Upper House Campaign Begins in Japan, Healthcare and Pharma-Linked Candidates in Spotlight
  July 3, 2025

ページ

• « 先頭
• ‹ Prev
• …
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• …
• Next ›
• 最終 »